Phase 2 N=100 A Study in Adults With Untreated Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Primary: Asparaginase Completion Rate — 63 Percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=308 Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant
Prophylaxis · Stem Cell Transplant Complications
Primary: Proportion of Bloodstream Bacterial Infections — 18; 18 participants
Phase 2 N=20 Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations
Immunosuppression · COVID-19
Primary: Change in Antibody Concentration From Baseline (Visit 1) at 1 Month (Visit 2) — 22968.5; 66639 Endotoxin Units per milliliter (EU/mL)
Phase 2 N=187 A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema
Diabetic Macular Edema
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48 in Treatment-naïve Participants — 12.8; 9.4 letters — p=0.0625
Phase 2 N=216 A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS
Acute Pancreatitis · Systemic Inflammatory Response Syndrome
Primary: Median Time to Solid Food Tolerance, With gMCP Modeling Analysis for Dose-response Relationship — 67.0; 64.0; 78.0; 66.0 Hours — p=0.3184
Phase 2 N=12 Anti-malaria MAb in Kenyan Children
Plasmodium Falciparum Infection · Malaria
Primary: Number of Participants With Local Adverse Events (AEs) — 0; 1; 1; 1 Participants
Phase 2 N=103 A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Change From Baseline in Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) at Week 12 — -1.86; -1.92 Score on a Scale — p==0.822
Phase 2 N=22 POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis
Atopic Dermatitis
Primary: Proportion of Patients Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 26 — 94.1 percentage of patients achieved EASI75
Phase 2 N=263 Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Alzheimer's Disease (AD)
Primary: Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 14) Score at Week 12 — -1.26; -1.28; -1.68; -1.01 score on a scale — p=0.9819
Phase 2 N=188 Early Communication Intervention for Toddlers With Hearing Loss
Hearing Loss, Bilateral
Primary: Use of Communication Support Strategies - Parent — .60; .02 units on a scale
Phase 2 N=24 A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide
Biochemically Recurrent Prostate Cancer
Primary: Percent Change in Serum Testosterone — 53.46 percentage (%)
Phase 2 N=112 A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia
Early Course Schizophrenia Spectrum Disorder
Primary: Neural Activity Across Brain Regions During a Spatial Working Memory (sWM) Task- Condition 2 — -0.076; -0.090; -0.072; -0.136 percentage signal change
Phase 2 N=25 A Single Ascending Dose Cohort Study of AG-73305 in DME Patients
Diabetic Macular Edema
Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) — 3.7; 9.2; 4.3; 7.7 ETDRS letters
Phase 2 N=72 A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults
COVID-19 · SARS-CoV-2 Infection · Corona Virus Infection
Primary: Number of Participants Reporting Solicited Local or Systemic Adverse Events (AEs) — 3; 4; 3; 5 Participants
Phase 2 N=33 A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Plaque Psoriasis
Primary: Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) — 18.8; 5.9 percentage of participants — p=0.316